Impaired presynaptic inhibition in the motor cortex in Parkinson disease

Neurology

Volumn 72, Issue 9, 2009, Pages 842-849

  Chu, J ^a   Wagle Shukla, A ^a   Gunraj, C ^a   Lang, A E ^a   Chen, R ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ENTACAPONE; LEVODOPA; PRAMIPEXOLE; ROPINIROLE; SELEGILINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EVOKED MUSCLE RESPONSE; FEMALE; HUMAN; MALE; MOTOR CORTEX; PARKINSON DISEASE; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; TRANSCRANIAL MAGNETIC STIMULATION; COMPARATIVE STUDY; ELECTROMYOGRAPHY; METHODOLOGY; MIDDLE AGED; NERVE CELL INHIBITION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTOSOME;

AGED; ELECTROMYOGRAPHY; EVOKED POTENTIALS, MOTOR; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR CORTEX; NEURAL INHIBITION; PARKINSON DISEASE; PRESYNAPTIC TERMINALS; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 62849091566     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000343881.27524.e8     Document Type: Article

References (40)

1. Kujirai T, Caramia MD, Rothwell JC, et al. Corticocortical inhibition in human motor cortex. J Physiol 1993;471:501-519.
2. Valls-Sole J, Pascual-Leone A, Wassermann EM, Hallett M. Human motor evoked responses to paired transcranial magnetic stimuli. Electroencephalogr Clin Neurophysiol 1992;85:355-364.
3. Ridding MC, Inzelberg R, Rothwell JC. Changes in excitability of motor cortical circuitry in patients with Parkinson's disease. Ann Neurol 1995;37:181-188.
4. Ziemann U, Lonnecker S, Steinhoff BJ, Paulus W. Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol 1996;40:367-378.
5. Strafella AP, Valzania F, Nassetti SA, et al. Effects of chronic levodopa and pergolide treatment on cortical excitability in patients with Parkinson's disease: a transcranial magnetic stimulation study. Clin Neurophysiol 2000;111:1198-1202.
6. Bares M, Kanovsky P, Klajblova H, Rektor I. Intracortical inhibition and facilitation are impaired in patients with early Parkinson's disease: a paired TMS study. Eur J Neurol 2003;10:385-389.
7. Hanajima R, Ugawa Y, Terao Y, Ogata K, Kanazawa I. Ipsilateral cortico-cortical inhibition of the motor cortex in various neurological disorders. J Neurol Sci 1996;140:109-116.
8. Mackinnon CD, Gilley EA, Weis-McNulty A, Simuni T. Pathways mediating abnormal intracortical inhibition in Parkinson's disease. Ann Neurol 2005;58:516-524.
9. Berardelli A, Rona S, Inghilleri M, Manfredi M. Cortical inhibition in Parkinson's disease: a study with paired magnetic stimulation. Brain 1996;119:71-77.
10. Valzania F, Strafella AP, Quatrale R, et al. Motor evoked responses to paired cortical magnetic stimulation in Parkinson's disease. Electroencephalogr Clin Neurophysiol 1997;105:37-43.
11. Pierantozzi M, Palmieri MG, Marciani MG, Bernardi G, Giacomini P, Stanzione P. Effect of apomorphine on cortical inhibition in Parkinson's disease patients: a transcranial magnetic stimulation study. Exp Brain Res 2001;141: 52-62.
12. Fierro B, Brighina F, D'Amelio M, et al. Motor intracortical inhibition in PD: L-DOPA modulation of high-frequency rTMS effects. Exp Brain Res 2008;184:521-528.
13. Sanger TD, Garg RR, Chen R. Interactions between two different inhibitory systems in the human motor cortex. J Physiol 2001;530:307-317.
14. Chu J, Gunraj C, Chen R. Possible differences between the time courses of presynaptic and postsynaptic GABA(B) mediated inhibition in the human motor cortex. Exp Brain Res 2008:184:571-577.
15. Werhahn KJ, Kunesch E, Noachtar S, Benecke R, Classen J. Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. J Physiol (Lond) 1999:517:591-597.
16. McDonnell MN, Orekhov Y, Ziemann U. The role of GABA(B) receptors in intracortical inhibition in the human motor cortex. Exp Brain Res 2006:173:86-93.
17. Müller-Dahlhaus JFM, Liu Y, Ziemann U. Inhibitory circuits and the nature of their interactions in the human motor cortex a pharmacological TMS study. J Physiol 2008:586:495-514.
18. Morgante F, Espay AJ, Gunraj C, Lang AE, Chen R. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain 2006:129:1059-1069.
19. Daskalakis ZJ, Molnar GF, Christensen BK, Sailer A, Fitzgerald PB, Chen R An automated method to determine the transcranial magnetic stimulation-induced contralateral silent period. Clin Neurophysiol 2003:114:938-944.
20. Ziemann U. TMS and drugs. Clin Neurophysiol 2004; 115:1717-1729.
21. Valls-Solé J, Pascual-Leone A, Brasil-Neto JP, Cammarota A, McShane L, Hallett M. Abnormal facilitation of the response to transcranial magnetic stimulation in patients with Parkinson's disease. Neurology 1994:44:735-741.
22. Bäumer T, Dammann E, Bock F, Kloppel S, Siebner HR, Miinchau A. Laterality of interhemispheric inhibition depends on handedness. Exp Brain Res 2007:180:195-203.
23. Priori A, Berardelli A, Inghilleri M, Accornero N, Manfredi M. Motor cortical inhibition and the dopaminergic system: pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson's disease and drug-induced parkinsonism. Brain 1994:117:317-323.
24. Chen R, Lozano AM, Ashby P. Mechanism of the silent period following transcranial magnetic stimulation: evidence from epidural recordings. Exp Brain Res 1999:128: 539-542.
25. Tergau F, Wanschura V, Canelo M, et al. Complete suppression of voluntary motor drive during the silent period after transcranial magnetic stimulation. Exp Brain Res 1999:124:447-454.
26. Davies CH, Davies SN, Collingridge GL. Paired-pulse depression of monosynaptic GABA-mediated inhibitory postsynaptic responses in rat hippocampus. J Physiol 1990:424:513-531.
27. Deisz RA. GABA(B) receptor-mediated effects in human and rat neocortical neurones in vitro. Neuropharmacology 1999:38:1755-1766.
28. Lambert NA, Wilson WA. Temporally distinct mechanisms of use-dependent depression at inhibitory synapses in the rat hippocampus in vitro. J Neurophysiol 1994:72: 121-130.
29. Vigot R, Barbieri S, Brauner-Osborne H, et al. Differential compartmentalization and distinct functions of GABAB receptor variants. Neuron 2006:50:589-601.
30. Henderson JM, Carpenter K, Cartwright H, Halliday GM. Degeneration of the centre median-parafascicular complex in Parkinson's disease. Ann Neurol 2000:47:345-352.
31. Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004:3:309-316.
32. Sailer A, Molnar GF, Paradiso G, Gunraj CA, Lang AE, Chen R. Short and long latency afferent inhibition in Parkinson's disease. Brain 2003:126:1883-1894.
33. Otis TS, Mody I. Differential activation of GABAA and GABAB receptors by spontaneously released transmitter. J Neurophysiol 1992:67:227-235.
34. Potier B, Dutar P. Presynaptic inhibitory effect of baclofen on hippocampal inhibitory synaptic transmission involves a pertussis toxin-sensitive G-protein. Eur J Pharmacol 1993:231:427-433.
35. Ni Z, Gunraj C, Chen R. Short interval intracortical inhibition and facilitation during the silent period in human. J Physiol 2007:583:971-982.
36. Ridding MC, Taylor JL, Rothwell JC. The effect of voluntary contraction on cortico-cortical inhibition in human motor cortex. J Physiol 1995:487:541-548.
37. Reynolds C, Ashby P. Inhibition in the human motor cortex is reduced just before a voluntary contraction. Neurology 1999;53:730-735.
38. Chen R, Kumar S, Garg RR, Lang AE. Impairment of motor cortex activation and deactivation in Parkinson's disease. Clin Neurophysiol 2001;112:600-607.
39. Lang AE. The progression of Parkinson disease: a hypothesis. Neurology 2007;68:948-952.
40. Clissold BG, McColl CD, Reardon KR, Shiff M, Kempster PA. Longitudinal study of the motor response to levodopa in Parkinson's disease. Mov Disord 2006; 21:2116-2121.